.Pharmacolibrary.Drugs.ATC.N.N05AE05 .Pharmacolibrary.Drugs.ATC.N.N05AE05| name: | Lurasidone |
| ATC code: | N05AE05 | route: | oral |
| n-compartments | 1 |
Lurasidone is an atypical antipsychotic medication approved for the treatment of schizophrenia and bipolar depression in adults and adolescents. It acts primarily as an antagonist at dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors. Lurasidone is currently approved and widely used.
Pharmacokinetic parameters for lurasidone in healthy adult subjects after oral administration. Data mainly reflect single-dose administration of 40 mg under fed conditions.
Hu, C, et al., & Jia, J (2017). Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects. Clinical drug investigation 37(9) 861–871. DOI:10.1007/s40261-017-0546-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28695535
Rado, J, & Janicak, PG (2012). Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. Drugs & aging 29(10) 783–791. DOI:10.1007/s40266-012-0009-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23018584
McGrane, IR, et al., & Munjal, RC (2021). Roux-en-Y Gastric Bypass and Antipsychotic Therapeutic Drug Monitoring: Two Cases. Journal of pharmacy practice 34(3) 503–506. DOI:10.1177/0897190020905467 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32067562